miR Scientific Is Transforming Cancer Management Into What It Should Be

miR Scientific, LLC is a healthcare company committed to transforming global cancer management by providing early and highly accurate detection, characterization, and monitoring of disease. The Company has developed the miR Disease Management Platform®, a proprietary, non-invasive platform for the effective management of targeted diseases, initially focused on urological cancers. The platform is powered by the miR Sentinel® Prostate Cancer Test, a liquid biopsy urine test that can accurately detect, classify, and monitor prostate cancer based on the interrogation of small-non-coding RNAs extracted from urinary exosomes.

Scientific Advisory Board

Andrew Armstrong, MD

Yuval Eshdat, Ph.D

Phillip C. Ginsberg, DO, JD

David Josephson, MD

Brianne Kent, PhD

James M. Libby, MD

Angel S. Muntaner Morales, MD

Chad Ritch, MD, MBA

Geoffrey Sonn, MD

Work At miR

Join a passionate, talented group of scientists, physicians, and business leaders to drive historic change in healthcare

miR Careers

miR Scientific is a majority-owned operating subsidiary of Huminn Inc. (formally know as Impact NRS), headquartered in New York with an operating subsidiaries in Israel.

Huminn LLC is a leading innovation company developing transformative solutions to address persistent global challenges in human health, sustainable food production and agriculture. Their model incorporates breakthrough advances in science, statistics and computation to develop products and services for early and scalable adoption. Huminn LLC collaborates with stakeholders worldwide to enable rapid commercialization of their ESG socially responsible initiatives.